HAYWARD — On the second day of the trial challenging the constitutionality of California's $3 billion stem cell institute, attorneys for the state defended the agency's track record through a key witness. Robert Klein, chairman of the board overseeing the California Institute for Regenerative Medicine, took the stand for most of the day, answering questions from both sides about the structure and content of the agency. Klein was the chief architect of Proposition 71, the ballot initiative approved by 59 percent of voters in November 2004 establishing the stem cell agency and authorizing the state to issue $300 million in...
